HOME >> MEDICINE >> NEWS
Retinoblastoma researchers find success with two-drug combination

Investigators at St. Jude Children's Research Hospital have demonstrated in laboratory studies a new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy, and more likely to prevent the recurrence of this cancer. A report on their work appears in the October 15 issue of Clinical Cancer Research.

Retinoblastoma is a tumor that arises in the cells of the retina, the light-sensitive tissue at the back of the eyeball, following mutation of the gene RB1. It is the third most common form of cancer in infants. Left untreated, the cancer spreads and is fatal. Retinoblastoma strikes about 250-350 infants and young children each year in the United States.

The St. Jude study suggests a new approach to treatment that could save both lives and vision, according to Michael A. Dyer, PhD, an assistant member of the department of Developmental Neurobiology. The new treatment might also prevent recurrence of retinoblastoma in children whose cancer is very advanced, he noted. Dyer is the senior author of the Clinical Cancer Care report.

The study showed that combination therapy with topotecan and carboplatin is superior to the standard triple-drug therapy using vincristine, carboplatin and etoposide. The new combination eliminates the use of etoposide, which is known to increase the risk of the children getting a form of leukemia called acute myeloblastic leukemia. The findings also suggest that vincristine, which is used in the standard combination therapy, contributes little to the treatment of retinoblastoma, and therefore can be eliminated from therapy.

Dyer's group was prompted to look for new treatments because of the difficulty in managing this cancer. Patients with retinoblastoma usually undergo enucleation (removal of the diseased eye); and children with retinoblastoma in both eyes often must undergo anticancer therapy in order to avoid the loss of both eyes and blindness.

But despi
'"/>

Contact: Kelly Perry
kelly.perry@stjude.org
901-495-3306
St. Jude Children's Research Hospital
17-Oct-2005


Page: 1 2 3

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
3. Penn researchers discover novel pathway for increasing good cholesterol
4. Theory of facial aging gets a facelift from UT Southwestern researchers
5. UIC researchers to develop new drugs to fight bioterrorism
6. UQ researchers discover some of the oldest forms of life
7. U of M researchers discover new method to combat HIV
8. U of M researchers assess effectiveness of computerized physician order entry system
9. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
10. Physician-researchers often less successful in obtaining NIH funding
11. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells

Post Your Comments:
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... Interrupting blood supply to an arm or a leg before ... surgery, according to a new study. "During heart ... heart to be able to operate on it. After some ... to produce energy because it doesn,t get oxygen. When we ... as an arm or a leg, the body prepares for ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Not getting the ... ulcerative colitis, a new study suggests. Those who ... eight hours per night may be more prone to ... intestines, researchers report. The study authors concluded that duration ... considered among patients with inflammatory bowel diseases. "Both ...
(Date:10/25/2014)... A large influx of international aid is needed, and ... thousands of deaths from the widening Ebola crisis, a ... a specially designed mathematical model, the researchers looked at ... densely populated county of hard-hit Liberia -- Montserrado County, ... researchers said that if international aid isn,t delivered to ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
Breaking Medicine News(10 mins):Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
(Date:10/25/2014)... , Oct. 24, 2014 Burzynski Research ... and Drug Administration (FDA) has given the company permission ... AS2-1 in patients > 3 months of age with ... be placed in one of five treatment groups based ... received prior treatment for DIPG. The primary study endpoint ...
(Date:10/22/2014)... 22, 2014  Cephasonics, a technology-innovation leader with a ... cQUB™-1 (cQuest Ultrasound Box™-1), the first product in a ... manufactured by Cephasonics for purchase by companies to rebrand ... will be showcasing the cQUB-1 for the first time ... Chongqing, China from October 23 ...
(Date:10/22/2014)... 22, 2014 Antigen Discovery Inc. (ADi), a ... , announced the receipt of a National Institutes of ... from the National Institute of Dental and Craniofacial Research (NIDCR). ... a Pan-HIV Protein Microarray Chip, which will contain every ... and aid in the development of safe and effective ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
Cached News: